Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/humrep/dew258 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Uncertain Prognostic Impact of Visceral Pleural Invasion-Reply.
JAMA Oncol
January 2025
Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina.
In Reply to Gad Et Al "Clinical Impact of New Reference Intervals for the Roche Prolactin II Immunoassay".
Clin Endocrinol (Oxf)
January 2025
Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
CURRENT METHODS FOR HALITOSIS DIAGNOSIS AND THE IMPACT OF COVID-19 PANDEMIC: AN INTERNATIONAL SURVEY.
J Breath Res
January 2025
Dentistry (periodontology), Katholieke Universiteit Leuven, Kapucijnenvoer 7, Leuven, Flanders, 3000, BELGIUM.
Halitosis specialists can be found all over the world, but very little is known about how they approach patients with halitosis complaints. Therefore, this web-based questionnaire study tried to reach as many of them to gain insight in their methods and tools used to diagnose the condition. Since this study was carried out in the aftermath of the COVID-19 pandemic, its impact was also examined.
View Article and Find Full Text PDFPharmacist-supported electronic outreach to address medication nonadherence for Medicare Advantage enrollees.
J Manag Care Spec Pharm
January 2025
University of Colorado, Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora.
Background: Improved medication adherence, represented as an increase in the proportion of days covered (PDC), to chronic medications is associated with better patient outcomes, yet effective strategies to improve adherence are often resource intensive. To quantify the impact of a pharmacist-supported electronic outreach initiative on medication adherence measures and to qualitatively evaluate patient engagement with and response to electronic messaging.
Methods: This retrospective cohort evaluation used mixed methods to assess the impact of a population health quality improvement program to address medication adherence for Medicare Advantage enrollees.
Reply: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment.
Hepatology
December 2024
Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, W120HS London, UK.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!